Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
What Skytrofa (previously Lonapegsomatropin Ascendis Pharma) is used for
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
- Active substance
- lonapegsomatropin
- Disease area
- Growth and Development
- Medicine group
- Pituitary and hypothalamic hormones and analogues
- ATC code
- H01AC09
- Marketing authorisation holder
- Ascendis Pharma Endocrinology Division A/S
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Skytrofa
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Skytrofa (previously Lonapegsomatropin Ascendis Pharma) used for?
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])
What is the active substance in Skytrofa (previously Lonapegsomatropin Ascendis Pharma)?
Skytrofa (previously Lonapegsomatropin Ascendis Pharma) contains lonapegsomatropin.
Who makes Skytrofa (previously Lonapegsomatropin Ascendis Pharma)?
The EU marketing authorisation holder is Ascendis Pharma Endocrinology Division A/S.
Is Skytrofa (previously Lonapegsomatropin Ascendis Pharma) an orphan medicine?
Yes. Skytrofa (previously Lonapegsomatropin Ascendis Pharma) is designated an orphan medicine in the EU, for a rare disease (Growth and Development).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU